Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.56 |
| ▸ | JAK1 | P23458 | 4/20 | 0.56 |
| ▸ | JAK3 | P52333 | 4/20 | 0.56 |
| ▸ | STAT6 | P42226 | 12/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12904999 | 0.82 | JAK2 (0.60) | JAK2JAK1JAK3STAT6SYK | |
| SCHEMBL2387160 | 0.80 | STAT6 (0.61) | JAK2JAK1JAK3STAT6SYK | |
| SCHEMBL12904539 | 0.79 | STAT6 (0.58) | JAK2JAK1JAK3STAT6SYK | |
| SCHEMBL12904538 | 0.77 | JAK2 (0.55) | JAK2JAK1JAK3STAT6SYK | |
| SCHEMBL2386600 | 0.77 | STAT6 (0.81) | JAK2JAK1JAK3STAT6SYK | |
| SCHEMBL14862458 | 0.76 | STAT6 (0.68) | JAK2JAK1JAK3STAT6SYK | |
| SCHEMBL13735485 | 0.74 | MAPK8 (0.51) | JAK2JAK1JAK3SYK | |
| SCHEMBL3712006 | 0.74 | RPS6KB1 (0.63) | JAK2JAK1JAK3STAT6AURKA | |
| SCHEMBL13734880 | 0.74 | MAPK8 (0.51) | JAK3SYK | |
| SCHEMBL14862758 | 0.74 | STAT6 (0.62) | JAK2JAK1JAK3STAT6SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-1518855-B1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | ASTELLAS PHARMA INC. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1518855-A1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | JAK2 6/4885JAK1 11/4885JAK3 10/4885 |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | STAT5A, STAT6, STAT4 | JAK2 7/4885JAK1 12/4885JAK3 11/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | JAK2 6/4885JAK1 11/4885JAK3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.